4ezm

Publication Abstract from PubMed

The role of IgE in allergic disease mechanisms is performed principally through its interactions with two receptors, FcepsilonRI on mast cells and basophils, and CD23 (FcepsilonRII) on B cells. The former mediates allergic hypersensitivity, the latter regulates IgE levels, and both receptors, also expressed on antigen-presenting cells, contribute to allergen uptake and presentation to the immune system. We have solved the crystal structure of the soluble lectin-like "head" domain of CD23 (derCD23) bound to a subfragment of IgE-Fc consisting of the dimer of Cepsilon3 and Cepsilon4 domains (Fcepsilon3-4). One CD23 head binds to each heavy chain at the interface between the two domains, explaining the known 2:1 stoichiometry and suggesting mechanisms for cross-linking membrane-bound trimeric CD23 by IgE, or membrane IgE by soluble trimeric forms of CD23, both of which may contribute to the regulation of IgE synthesis by B cells. The two symmetrically located binding sites are distant from the single FcepsilonRI binding site, which lies at the opposite ends of the Cepsilon3 domains. Structural comparisons with both free IgE-Fc and its FcepsilonRI complex reveal not only that the conformational changes in IgE-Fc required for CD23 binding are incompatible with FcepsilonRI binding, but also that the converse is true. The two binding sites are allosterically linked. We demonstrate experimentally the reciprocal inhibition of CD23 and FcepsilonRI binding in solution and suggest that the mutual exclusion of receptor binding allows IgE to function independently through its two receptors.

Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor Fc{varepsilon}RI.,Dhaliwal B, Yuan D, Pang MO, Henry AJ, Cain K, Oxbrow A, Fabiane SM, Beavil AJ, McDonnell JM, Gould HJ, Sutton BJ Proc Natl Acad Sci U S A. 2012 Jul 16. PMID:22802656^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.